Download

Full Text

• Herrman H, Kieling C, McGorry P, et al. Reducing the global burden of depression: a lancet–world psychiatric association commission. The Lancet. 2019;393(10189):e42–e43. doi: 10.1016/S0140-6736(18)32408-5
• Corriger A, Pickering G., Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019;13:3051–3067. doi: 10.2147/DDDT.S221437
• McAllister-Williams RH, Arango C, Blier P, et al. The identification, assessment, and management of difficult-to-treat depression: an international consensus statement. J Affect Disord. 2020;267:264–282. doi: 10.1016/j.jad.2020.02.023
• Grunebaum MF, Galfalvy HC, Choo T-H, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. doi: 10.1176/appi.ajp.2017.17060647
• Bahji A, Vazquez GH, Zarate CA, Jr.Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555. doi: 10.1016/j.jad.2020.09.071
• Zanos P, Gould TD., Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–811. doi: 10.1038/mp.2017.255
• Abdallah CG, Sanacora G, Duman RS, et al. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509–523. doi: 10.1146/annurev-med-053013-062946
• Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709. doi: 10.1016/j.jpsychires.2022.04.037
• Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021;35(2):109–123. doi: 10.1177/0269881120959644
• Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592–1603. doi: 10.1038/s41380-018-0256-5
• Zhang, Jc, Li, Sx, Hashimoto K. R(−)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141. doi: 10.1016/j.pbb.2013.11.033
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. doi: 10.1176/appi.ajp.2020.20081251
• Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2020;81(4):19r12889. doi: 10.4088/JCP.19r12889
• Popova V, Ej D, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438. doi: 10.1176/appi.ajp.2019.19020172
• Reif A, Bitter I, Buyze J, et al. ESCAPE-TRD Investigators. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389(14):1298–1309. doi: 10.1056/NEJMoa2304145
• Loo CK, Gálvez V, O’Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular, and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48–56. doi: 10.1111/acps.12572
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826. doi: 10.1176/appi.ajp.2016.16010037
• Rosenblat JD, Carvalho AF, Li M, et al. Oral ketamine for depression: a systematic review. J Clin Psychiatry. 2019;80(3):18r12475. doi: 10.4088/JCP.18r12475
• Meshkat S, Haikazian S, Di Vincenzo JD, et al. Oral ketamine for depression: An updated systematic review. World J Biol Psychiatry. 2023;24(7):545–557. doi: 10.1080/15622975.2023.2169349
• Chang L, Zhang K, Pu Y, et al. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav. 2019;181:53–59. doi: 10.1016/j.pbb.2019.04.008
• Yang C, Shirayama Y, Zhang J, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632. doi: 10.1038/tp.2015.136
• Zhang JC, Li SX, Hashimoto KR. R(−)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–41. doi: 10.1016/j.pbb.2013.11.033
• Leal GC, Bandeira ID, Correia-Melo FS, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2020;271(3):577–582. doi: 10.1007/s00406-020-01110-5
• Bonaventura J, Lam S, Carlton M, et al. Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability. Mol Psychiatry. 2021;26(11):6704–6722. doi: 10.1038/s41380-021-01093-2
• Nguyen L, Lucke-Wold BP, Mookerjee SA, et al. Role of sigma-1 receptors in neurodegenerative diseases. J Pharmacol Sci. 2015;127(1):17–29. doi: 10.1016/j.jphs.2014.12.005
• Salaciak K, Pytka K. Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders. Neurosci Biobehav Rev. 2022;132:1114–1136. doi: 10.1016/j.neubiorev.2021.10.037
• Lii, Tr, Smith, Ae, Flohr JR, et al. Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nat Ment Health. 2023;1(11):876–886. doi: 10.1038/s44220-023-00140-x
• Rhee TG, Shim SR, Forester BP, et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79(12):1162–1172. doi: 10.1001/jamapsychiatry.2022.3352
• Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315–2325. doi: 10.1056/NEJMoa2302399
• UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. The Lancet. 2003;361(9360):799–808. doi: 10.1016/S0140-6736(03)12705-5
• Jiang Y, Du Z, Shen Y, et al. The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur Arch Psychiatry Clin Neurosci. 2023. doi: 10.1007/s00406-023-01732-5
• Zaki N, Chen LN, Lane R, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacol. 2023Jul;48(8):1225–1233. doi: 10.1038/s41386-023-01577-5
• Chang M, Juruena MF, Young AH. Ketamine cystitis following ketamine therapy for treatment-resistant depression - case report. BMC Psychiatry. 2024Jan2;24(1):9. doi: 10.1186/s12888-023-05468-3